

Contents

Series Editors Preface *xvii*

Preface *xix*

- 1 Impact of Poor Solubility on Drug Development** *1*
Preshita Desai
- 1.1 Introduction *1*
 - 1.2 Drug Solubility *2*
 - 1.3 Impact of Poor Drug Solubility on Drug-Like Properties *4*
 - 1.4 Addressing Poor Drug Solubility Challenge *5*
 - 1.4.1 Drug Material Engineering *6*
 - 1.4.1.1 Particle Size Engineering *6*
 - 1.4.1.2 Modulating Drug Properties: Salts, Solvates, Polymorphs, and Co-crystals *6*
 - 1.4.1.3 Prodrugs *8*
 - 1.4.2 Drug Formulation Approaches *9*
 - 1.4.2.1 Cosolvency, Hydrotrophy, and Solubilizing Agents *9*
 - 1.4.2.2 Cyclodextrin Inclusion Complexes *10*
 - 1.4.2.3 Solid Dispersions and Solid Solutions *10*
 - 1.4.2.4 Nanoformulation Spectrum *11*
 - 1.5 Poor Drug Solubility—Is It Always a Challenge? *13*
 - 1.6 Conclusion *14*
 - References *15*
- 2 Design and Development of Amorphous Solid Dispersion as Enabling Formulation Strategies of Poorly Soluble Drugs** *19*
Amrit Paudel and Sarah Stryeck
- 2.1 Basics of Amorphous Solid Dispersion (ASD) *19*
 - 2.1.1 Introduction *19*
 - 2.1.2 Basic Design Principles of ASD *20*
 - 2.1.3 Design Attributes of ASD *20*
 - 2.1.3.1 Intrinsic Amorphization Potential of API *21*
 - 2.1.3.2 Drug–Polymer Phase Behavior *22*

2.1.3.3	Molecular Mobility in ASD	23
2.1.3.4	Drug–Polymer Interactions	24
2.1.4	Formulation Basis of ASD Products	25
2.1.4.1	Polymers Used in ASD	26
2.1.4.2	Drug Loading Selection	27
2.2	Analytical Characterization of ASDs	28
2.2.1	Drug–Polymer Phase Behavior	29
2.2.2	Molecular Mobility	31
2.2.3	Characterization of Molecular Interactions in ASD	33
2.2.4	Crystallinity Analysis in ASD	35
2.2.5	Surface Analysis of ASD	36
2.2.6	Bulk and Powder Characterization of ASD	37
2.2.7	Miscellaneous Analysis of ASD	38
2.3	Preformulation and Screening of ASD	38
2.3.1	Biopharmaceutics Screening	39
2.3.2	Composition Screening	39
2.3.3	Process-Relevant Screening	40
2.4	Manufacturing Processes of ASD	40
2.4.1	Spray Drying	42
2.4.2	Hot Melt Extrusion	42
2.4.3	Other Technologies	44
2.4.4	Downstream Processing of ASD	45
2.5	Biopharmaceutics of ASD	46
2.5.1	Solubility, Supersaturation, and Nano-colloids	46
2.5.2	Drug Dissolution from ASD	48
2.5.3	In Vivo and Ex Vivo Aspects of ASD	49
2.6	Stability Considerations of ASD	50
2.6.1	Physical Stability Assessment of ASD	51
2.6.2	Chemical Stability Assessment of ASD	52
2.6.3	Product Performance Stability Assessment of ASD	53
2.7	Computational Tools for ASD Development	54
2.7.1	Thermodynamic and Phenomenological Models	55
2.7.2	Multiscale Molecular Simulation and Modeling	56
2.7.3	Macroscale Modeling	57
2.7.4	Biopharmaceutics Modeling	58
2.7.5	Data-Driven and Hybrid Modeling	59
2.8	Emerging Innovations in ASD	59
	References	60
3	Nanosizing of Drugs to Improve the Apparent Dissolution and Bioavailability	81
	<i>Yalamanda Varla, Vishvesh Joshi, Rikin Patel, and Derajram Benival</i>	
3.1	Introduction	81
3.1.1	Importance of Solubility and Dissolution in Drug Bioavailability	81
3.1.2	Challenges in Formulating Poorly Water-Soluble Drugs	82

3.1.3	Noyes–Whitney Equation and Surface Area Relationship	83
3.1.4	Overview of Particle Size Reduction Technologies	84
3.1.5	Role of Nanosizing in Enhancing Dissolution and Bioavailability	84
3.1.6	Traditional Versus Nanosizing Techniques in Solubility Enhancement	84
3.2	Techniques for Nanosizing	87
3.2.1	Top-Down Approaches	87
3.2.1.1	Wet Media Milling	88
3.2.1.2	High-Pressure Homogenization	89
3.2.1.3	Ultrasonication	90
3.2.2	Bottom-Up Approaches	91
3.2.2.1	Precipitation Techniques	91
3.2.2.2	Supercritical Fluid Technology	91
3.2.2.3	Solvent Evaporation	92
3.2.3	Hybrid and Advanced Approaches	92
3.2.3.1	Combination Techniques (Microprecipitation and Homogenization)	92
3.3	Formulation Strategies for Nanosized Drugs	93
3.3.1	Nanocrystals and Nanosuspension	94
3.3.2	Nanoemulsions	95
3.3.3	Marketed Nanosized Drug Formulations	96
3.4	Challenges and Limitations in Nanosizing	96
3.4.1	Stability Issues	96
3.4.2	Scale-Up and Manufacturing Constraints	96
3.4.3	Regulatory Considerations and Safety Concerns	98
3.5	Future Perspectives	98
3.6	Conclusion	99
	References	99
4	Pharmaceutical Cocrystals	115
	<i>Ghaida Mustafa, Shahzeb Khan, and Anant Paradkar</i>	
4.1	Introduction	115
4.1.1	Pharmaceutical Cocrystals and Importance in the Pharmaceutical Industry	115
4.1.2	Fundamentals of Pharmaceutical Cocrystals	115
4.1.2.1	Historical Background	115
4.1.2.2	Basic Concept and Definitions	116
4.1.2.3	Differences Between Cocrystals, Salts, and Polymorphs	118
4.1.2.4	Selection of Coformers	118
4.2	Synthon Theory and Prediction Tools in Cocrystal Design	119
4.2.1	Definition, Importance, and Types of Synthons in Pharmaceutical Cocrystals	119
4.2.2	Computational Approaches and Software Tools for Cocrystal Screening	119
4.2.2.1	Quantum-Mechanical Methods	120
4.2.2.2	Molecular Docking and Molecular Dynamics Simulation	122

4.2.2.3	Crystal Structure Prediction and Lattice Energy Minimization	123
4.2.2.4	Semi-empirical Screening Methods	123
4.2.2.5	Machine Learning and Data-Driven Techniques	123
4.2.2.6	Database and Knowledge-Based Approaches	124
4.3	Synthesis of Pharmaceutical Cocrystals	124
4.3.1	Solid-State Approaches	125
4.3.1.1	Dry and Solvent-Assisted Grinding	125
4.3.1.2	Twin-Screw Extrusion Method	126
4.3.1.3	Hot Melt Extrusion Method	126
4.3.2	Cocrystals from Solutions	126
4.3.2.1	Evaporation Cocrystallization	128
4.3.2.2	Cooling Crystallization	128
4.3.2.3	Slurry Method	128
4.3.2.4	Anti-solvent Precipitation Method	129
4.3.3	Supercritical Fluid-Based Methods	129
4.3.3.1	Cocrystallization with Supercritical Solvent	129
4.3.3.2	Rapid Expansion of Supercritical Solvents	129
4.3.3.3	Supercritical Anti-solvent (SAS) Approach	130
4.3.3.4	Supercritical Assisted Spray Drying (SASD)	131
4.3.4	Miscellaneous Methods	131
4.3.4.1	Spray Drying	131
4.3.4.2	Freeze Drying	131
4.3.4.3	Ultrasound-Assisted Approach	131
4.4	Characterization Techniques of Pharmaceutical Cocrystals	132
4.4.1	Powder X-ray Diffraction (PXRD) and Single-Crystal X-ray Diffraction (XRD) Analysis	132
4.4.2	Thermal Analysis	132
4.4.2.1	Differential Scanning Calorimetry (DSC)	132
4.4.2.2	Thermogravimetric Analysis (TGA)	133
4.4.2.3	Hot Stage Microscopy (HSM)	134
4.4.3	Spectroscopic Techniques	135
4.4.3.1	Fourier Transform Infrared (FTIR) Spectroscopy	135
4.4.3.2	Raman Spectroscopy	136
4.4.3.3	Solid-State Nuclear Magnetic Resonance (SSNMR)	136
4.4.4	Microscopy Techniques	138
4.4.4.1	Scanning Electron Microscopy (SEM)	138
4.5	Solubility Aspects of Pharmaceutical Cocrystals	139
4.5.1	Thermodynamic Principles of Solubility	139
4.6	Pharmaceutical Cocrystals: Physicochemical Properties and Applications	141
4.6.1	Application of Pharmaceutical Cocrystals for Formulation Advantages	141
4.6.1.1	Cocrystals and Physical Stability	141
4.6.1.2	Cocrystals and Chemical Stability	142

4.6.1.3	Cocrystals to Tailor Optical Property	146
4.6.1.4	Cocrystals and Mechanical Properties	146
4.6.2	Application of Pharmaceutical Cocrystals for Pharmacokinetic Advantages	148
4.6.2.1	Enhancement of Bioavailability	148
4.6.2.2	Modulation of Drug Release Profiles	148
4.6.3	Application of Pharmaceutical Cocrystals for Therapeutic Advantages	149
4.7	Regulatory Considerations and Approval Pathways	151
4.8	Commercially Available Cocrystals-Based Pharmaceuticals	153
4.9	Challenges and Future Perspectives	153
4.9.1	Challenges in Cocrystals-Based Product Development	153
4.9.2	Multidrug Cocrystals	154
4.9.3	Drug–Nutraceutical Cocrystals	154
4.9.4	Nano-cocrystals	155
4.9.5	Process Analytical Technology and Cocrystals	155
4.9.6	Cocrystal Polymorphism	156
4.10	Conclusion	156
	List of Abbreviations	157
	References	157

5 Self-Microemulsifying and Self-Emulsifying Drug Delivery Systems to Improve Solubility and Bioavailability 173

Dipak B. Bari, Rakhee Kapadia, Raju O. Sonawane, Kamallesh D. Mali, Vivek P. Rajkule, Mahesh G. Umbarkar, and Chandrakantsing V. Pardeshi

5.1	Introduction	173
5.2	Self-Emulsifying Drug Delivery Systems	174
5.2.1	Self-Microemulsifying Drug Delivery System	174
5.2.1.1	Formulation Development	174
5.2.2	Self-Nanoemulsifying Drug Delivery System	174
5.3	Advantages and Disadvantages of SEDDS/SMEDDS	175
5.4	Formulation of SEDDS and SMEDDS	175
5.4.1	Oils/Lipids	178
5.4.2	Surfactants	178
5.4.3	Co-surfactant	179
5.4.4	Active Pharmaceutical Ingredients	182
5.5	Challenges in Formulation Development of SEDDS/SMEDDS	182
5.5.1	Drug Precipitation	183
5.5.2	Handling and Stability	185
5.5.3	Limited Lymphatic Uptake	185
5.5.4	Lack of Prognostic In Vitro Tests	185
5.5.5	Encapsulation in Soft Gelatin Capsules	185
5.5.6	Oxidation of Lipid Excipients	186
5.5.7	Polymorphism of Lipid Excipients	186

5.6	Mechanism of Self-Emulsification	187
5.7	Self-Emulsification and Uptake of Drugs In Vivo	187
5.8	Applications of SEDDS	188
5.8.1	SEDDS/SMEDDS for Nasal Drug Delivery	188
5.8.2	SEDDS/SMEDDS for Oral Drug Delivery	189
5.8.3	SEDDS/SMEDDS for Parenteral Delivery	191
5.9	Regulatory Updates on SMEDDS/SNEDDS	194
5.10	Commercial SEDDS	194
5.11	Patents on SEDDS	195
5.12	Clinical Status of SEDDS Formulations	195
5.13	Conclusion	195
	References	198
6	Liposomes and Mixed Micelles for Improvement of Drug Solubility	209
	<i>Chukwuebuka E. Umeyor, Diksha Narula, Ankita Anure, Andrew Ezegbe, Prafull Kolekar, and Vandana B. Patravale</i>	
6.1	Introduction	209
6.2	Drug Carrier Solubility Enhances Drug Bioavailability	210
6.3	Process Development of Liposomes	211
6.3.1	Liposomes Composition	211
6.3.2	Formulation Methods	213
6.3.2.1	Thin Film Hydration Method	213
6.3.2.2	Reverse Phase Evaporation	213
6.3.2.3	Detergent Removal Method	213
6.3.2.4	Solvent Injection Method	214
6.3.3	Drug Loading Improvement in Liposomes	215
6.3.4	Analysis of Drug Encapsulation	218
6.3.5	Stability of Liposomes	219
6.3.6	Types of Liposomes	220
6.3.6.1	Gas-Entrapped (Bubble) Liposomes	221
6.3.6.2	Charged Liposomes	222
6.3.6.3	Stimuli-Triggered Liposomes	224
6.3.6.4	Conventional Liposomes	225
6.3.6.5	Targeted Liposomes	227
6.4	Mixed Micelles for Enhanced Drug Solubility	228
6.4.1	Types of Mixed Micelles	229
6.4.1.1	Copolymer-Mixed Micelles	229
6.4.1.2	PEGylated Lipid Micelles	229
6.4.1.3	Stimuli-Sensitive Micelles	231
6.4.2	Method Used to Prepare Mixed Micelles	232
6.4.3	Concept of Critical Micelle Concentration	232
6.4.4	Cloud Point of Micelles	233
6.5	In vivo Safety of Liposomes and Mixed Micelles Drug Carriers	233
6.6	Benefits and Limitations of Liposomes and Mixed Micelles	234

6.6.1	Targeted Drug Delivery	234
6.6.2	Cell Targeted Drug Delivery	235
6.6.3	Controlled and Sustained Drug Delivery	235
6.6.4	Intraperitoneal Drug Delivery	235
6.6.5	Delivery of Vaccines	235
6.6.6	Enhancement in Pharmacokinetic and Dynamic Properties of Actives	235
6.6.6.1	Limitations of Liposomes and Mixed Micelles as Drug Delivery Carriers	236
6.7	Marketed Micellar and Liposomal Products	237
6.8	Regulatory Guidelines for Liposomes and Mixed Micelles Use	237
6.9	Clinical Application of Liposomes and Mixed Micelles	241
6.9.1	Application in Drug Delivery	241
6.9.2	Application in Clinical Diagnosis and Imaging	242
6.9.3	Application in Vaccine and Gene Delivery	243
6.10	Patent Landscape of Liposomes and Mixed Micelles	244
6.11	Future Research and Conclusion	244
	References	245
7	Improvement of Solubility and Bioavailability of Poorly Soluble Drugs Using Mesoporous Silica Particles	257
	<i>Jitendra Wankar and Sonia Gera</i>	
7.1	Introduction	257
7.2	Different Techniques for Synthesis of Silica Particles	258
7.2.1	Sol–Gel Method	258
7.2.2	Microemulsion Method	258
7.2.3	Template-Assisted Synthesis	259
7.3	Characterization of MSN	260
7.3.1	Particle, Pore Size, Their Distribution, and Morphology	260
7.3.2	Crystallinity and Nature	261
7.4	Mesoporous Silica for Drug Dissolution and Dosage Form Development	261
7.5	Drug-Loading Methods in Mesoporous Silica Particles to Improve Drug Solubility	262
7.5.1	Solvent-Based Method	264
7.5.2	Solvent-Free Methods	266
7.6	Mesoporous Silica Particles as a Potential Option to Improve Bioavailability (BA)	267
7.6.1	Stealth Particle by PEGylation to Prevent Opsonization	267
7.6.2	Cyclodextrin as a Gatekeeper on Silica for Controlled Release	268
7.6.3	Targeted Drug Delivery by Silica Conjugates	268
7.6.4	Improved Drug Stability by Protecting Drug from Gut Enzymatic Degradation	269
7.7	Commercial Success and Clinical Pipeline Using This Technology	269

7.8	Challenges Toward Clinical Translation of Mesoporous Silica Particles	270
7.9	Future Prospects and Conclusions	271
	Abbreviations	271
	References	272
8	Gastrointestinal Dissolution and Absorption of BCS Class II Drugs	277
	<i>Almog Eliyahu Dahan and Arik Dahan</i>	
8.1	Introduction	277
8.2	Drug Absorption and the BCS	277
8.3	GI Physiological Variables Affecting BCS Class II Drug Dissolution	280
8.3.1	Bile Salts	281
8.3.2	GI pH	281
8.3.3	GI Transit	282
8.3.4	Drug Particle Size	283
8.3.5	Volume Available for Dissolution	283
8.4	In vitro Dissolution Tests for Class II Drugs	284
8.4.1	Biorelevant Media	284
8.4.2	Dynamic Lipolysis Model	284
8.4.3	BCS-Based FDA/EMA Guidelines: Implications for Class II Drugs	285
8.5	Biowaiver Extension Potential	285
8.6	Advanced Simulation Models for FDA Biowaiver Submission	286
8.7	Conclusions	288
	Abbreviations	288
	Symbols	289
	References	289
9	Cyclodextrin-Based Formulations to Improve Solubility of Poorly Soluble Drugs	297
	<i>Ganesh Shevalkar, Shradhha Tiwari, Deepak Bari, Chandrakantsing Pardeshi, and Sarika Kamble</i>	
9.1	Introduction	297
9.1.1	Overview of Cyclodextrins (CDs)	297
9.1.2	Definition and Structural Properties	297
9.1.3	Historical Perspective of CDs in Drug Formulations	298
9.1.4	Importance in Drug Delivery	298
9.2	CD Structure and Types	298
9.2.1	Alpha, Beta, and Gamma CDs	298
9.2.2	CDs for Enhancing Bioavailability of Pharmaceutical Compounds	299
9.2.2.1	Role of CDs in Enhancing Bioavailability	300
9.2.3	Derivatives and Modified CDs	300
9.2.3.1	Substitution Reactions	301
9.2.3.2	Deoxy CDs	303
9.2.3.3	O-Substituted CDs	303

9.2.3.4	Esterification	304
9.2.3.5	Oxidation	304
9.3	Approved CD-Based Pharmaceutical Formulations	304
9.3.1	CD-Based Products Containing Blockbuster Drugs	305
9.3.2	Successful CD-Based Formulations and Their Commercial Impact	305
9.3.2.1	Veklury®: A Success Story	306
9.4	Drug Delivery Applications of CD-Based Formulations	306
9.4.1	Oral Delivery	306
9.4.1.1	Parenteral Delivery	307
9.4.1.2	Transdermal Delivery	309
9.4.1.3	Nasal Delivery	309
9.4.1.4	Ocular Delivery	310
9.4.1.5	Rectal Delivery	310
9.5	Current Landscape Post Approval of Captisol®	311
9.6	Regulatory and Clinical Landscape of Cyclodextrin-Based Biomaterials	312
9.6.1	Regulatory Challenges and Considerations	312
9.6.2	Manufacturing and Scale-Up Challenges	314
9.7	Toxicological Considerations of CDs with Emphasis on Renal Safety	314
9.7.1	Route-Dependent and Dose-Related Toxicity	314
9.7.2	Inclusion Complexes and Drug-Associated Toxicity	315
9.7.3	Hepatic and Metabolic Considerations	315
9.8	Patent Scenario Regarding the Use of CD	316
9.8.1	Areas of Patent Focus	316
9.8.2	Notable Patented Products and Technologies	317
9.8.3	Patentability Considerations	317
9.8.4	Manufacturing and Patent Challenges	317
9.8.5	Future Directions	318
9.9	Conclusion	318
	References	318
10	Cosolvent-Based Formulations to Improve Solubility and Bioavailability	327
	<i>Nilam Bhusare, Chetana Eknure, Yogeshwar Bachhav, and Maushmi S. Kumar</i>	
10.1	Background of the Cosolvent-Based Formulations	327
10.2	Cosolvency	328
10.2.1	Theory	329
10.2.2	Concept of Solubility	330
10.2.3	Advantages of Cosolvency	334
10.2.4	Disadvantages of Cosolvency	334
10.3	Types of Cosolvents Allowed and Their IIG Limits	334
10.4	Possible Adverse Events Due to the Use of Cosolvents—Case Studies	336

10.4.1	Diethylene Glycol Poisoning	336
10.4.2	Propylene Glycol Toxicity	337
10.5	Challenges in Selecting a Formulation in the Preclinical Studies Using Cosolvents	337
10.6	Design of Formulations Using Cosolvents for First-in-Man Studies or Late Clinical Phases	339
10.7	Regulatory Aspects	339
10.8	Selected Examples of Cosolvent-Based Formulations Using 505(b)(2) Pathway and Intellectual Property (IP) Protection	340
10.8.1	Cosolvent-Comprised Formulations for Hydrophobic Drug Solubilization	341
10.8.2	pH-Modified Cosolvent Formulations for Ionizable Drugs	342
10.8.3	Surfactant–Cosolvent Hybrids for Use in Oral and Transdermal Delivery	343
10.8.4	Solid Dispersion for Solubility Enhancement	343
10.9	Clinical Pipeline	344
10.10	Future Prospects	345
10.11	Conclusion	345
	Acknowledgment	346
	References	346
11	First-in-Animal Studies and Formulation Considerations	353
	<i>Dnyaneshwar N. Kapote and Vandana Gawande-Kapote</i>	
11.1	Introduction	353
11.2	Steps in Preclinical Studies	355
11.2.1	Pharmacological/Pharmacodynamic Study	355
11.2.2	Pharmacokinetic Study	355
11.2.3	Toxicokinetic Study	356
11.3	Pre-Formulation Considerations for First-in-Animal Studies (Preclinical Formulations)	356
11.3.1	Solubility Studies	358
11.3.2	Lipophilicity and <i>in vitro</i> Permeability	360
11.3.3	Ionization Constant (pK_a)	361
11.3.4	Physical State and Polymorphism	362
11.4	Formulation Considerations for First-in-Animal Formulations	363
11.4.1	Biopharmaceutical Classification System (BCS) and Its Application	363
11.4.2	Choice of Excipients and Its Applications in First-in-Animal Studies	364
11.4.3	Conventional Approach	365
11.4.3.1	Oral Gavage	365
11.4.3.2	Oral Solution	366
11.4.3.3	Oral Suspension	366
11.4.3.4	Oral Mini-Tablet/Mini-Capsule	367
11.4.4	Specialized/Enabling Formulations Approach	367
11.4.4.1	Amorphous Solid Dispersions (ASDs)	368

11.4.4.2	Lipid-Based Systems	372
11.4.4.3	Nanosuspensions	375
11.5	Bridging the Gap of First-in-Animal Studies with First-in-Human Studies	377
11.6	Conclusions	378
	References	379
12	Improving Aqueous Solubility of Drug Candidates Through Structural Modifications	389
	<i>Kamal Kumar</i>	
12.1	Introduction	389
12.2	Enhancing Drug Solubility and Bioavailability: A Key to Effective Therapy	391
12.3	Chemical Modification as a Strategy to Enhance Solubility	394
12.3.1	Structure (Chemical) Modification to Enhance Solubility	395
12.3.1.1	Introduction of Polar or Ionizable Appendages	396
12.3.1.2	Role of Small Key Modifications Including H-Bonding Modifiers to Improve Aqueous Solubility	401
12.3.1.3	Improvement of Solubility by Disruption of Molecular Planarity and Symmetry	403
12.3.1.4	Bioisosterism to Address Aqueous Solubility	404
12.3.1.5	Prodrug Approach to Address Aqueous Solubility	407
12.3.1.6	Other Miscellaneous Approaches to Address Weak Aqueous Solubility	409
12.4	Conclusion	410
	References	411
	Index	419

